Schematic illustration of the new MOF Antibody crystals and their ability to specifically seek out cancer cells to detect them and deliver highly potent drugs with unprecedented precision.
CREDIT: Dr Francesco Carraro and Prof Paolo Falcaro (Co-First and Co-Senior author on the Advanced Materials Paper)
It sounds like the stuff of science fiction: a man-made crystal that can be attached to antibodies and then supercharge them with potent drugs or imaging agents that can seek out diseased cells with the highest precision, resulting in fewer adverse effects for the patient.
However, that is precisely what researchers from the Australian Centre for Blood Diseases at Monash University in collaboration with the TU Graz (Austria) have developed: the world’s first metal-organic framework (MOFs) antibody-drug delivery system that has the potential to fast-track potent new therapies for cancer, cardiovascular and autoimmune diseases.
The in vitro study showed that when MOF antibody crystals bind to their target cancer cells and if exposed to the low pH in the cells, they break down, delivering the drugs directly and solely to the desired area.
The metal-organic framework, a mixture of metal (zinc) and carbonate ions, and a small organic molecule (an imidazole, a colourless solid compound that is soluble in water) not only keeps the payload attached to the antibody but can also acts as a reservoir of personalised therapeutics. This is a benefit with the potential to become a new medical tool to target specific diseases with customised drugs and optimised doses.
The findings are now published in the world-leading journal Advanced Materials.
Co-senior author Professor Christoph Hagemeyer, Head of the NanoBiotechnology Laboratory at the Australian Centre for Blood Diseases, Monash University, says while more funding is needed to take the research into the next phase and to patients, the new method is cheaper, faster and more versatile than anything available currently.
“The method offers the opportunity to personalise treatment and given the precision possible, may eventually change the current dosage needed for patients, resulting in fewer side effects and making treatments cheaper,” said Professor Hagemeyer.
Co-first author Dr Karen Alt, Head of the Nano Theranostics Laboratory at the Australian Centre for Blood Diseases, Monash University, says: “With just 0.01 per cent of chemotherapy currently reaching the cancer tissue, this revolutionary new method can boost the potency of the drugs reaching their target.”
“With over 80 different monoclonal antibodies approved for clinical use, this approach has enormous potential to improve these antibodies for the targeted delivery of diagnostic agents and therapeutic drugs. The goal is that ultimately the clinical translation of this technology will improve the quality of life for patients suffering from serious diseases,” said Dr Alt.
Original Article: Researchers develop a world-first antibody-drug delivery system
More from: Monash University | Graz University of Technology
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Antibody-drug delivery system
- New lupus treatments offer a better chance for remission
One of the most difficult things about lupus, a chronic autoimmune disease, is that people who have it don't always realize it—they know something's not right, but they're not sure what. They may feel ...
- Tiziana Life Sciences says study using nasal anti-CD3 (Foralumab) presented at the Alzheimer's Association International Conference
The study was presented virtually at the AAIC by Dr Howard L. Weiner, co-director of the Ann Romney Center for Neurologic Diseases at ...
- Mutual of America Capital Management LLC Cuts Stake in Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
Mutual of America Capital Management LLC lowered its position in shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating) by 4.2% in the first quarter, Holdings Channel reports. The ...
- HIV and AIDS News
July 25, 2022 — Researchers have examined five SARS-CoV-2 variants to determine how each strain interacts with the innate arm of the immune system ... for Delivery of Anti-HIV Antibody ...
- Biotium introduces new line of antibodies for exosome detection
ExoBrite™ Antibody Conjugates are validated and optimized for bright and specific detection of exosome markers CD9, CD63, and CD81 for flow cytometry and western blotting.
Go deeper with Google Headlines on:
Antibody-drug delivery system
Go deeper with Bing News on:
Metal-organic framework antibody-drug delivery
- Chemical communications (Cambridge, England)
Asymmetric organocatalytic vinylogous Michael addition triggered triple-cascade reactions of 2-hydroxycinnamaldehydes and vinylogous nucleophiles: construction of benzofused oxabicyclo[3.3.1 ...
- Student research into 2D materials is shaping the future of our 3D world
Amelia works specifically with zinc-based MONs, but there is the full range of metals in the periodic table to choose from and over 90,000 metal-organic frameworks known ... like imaging and drug ...
- Volume 6
synergistic checkpoint blockade and radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks, in vivo genome editing via disruption of Cas9 activity in the liver, a brain-wide ...
- Two-step synthesis procedure produces amino acid Schiff base Cu (II) complexes within 10 minutes
The insights from this study can be used as a framework for the development of fast and facile synthesis techniques for biologically active amino acid derivatives of Schiff base metal complexes.
- Microbiology & Immunology 2017
Being able to explore this biodiversity and use new knowledge for drug discovery and biotechnology applications is an exciting and expanding area of research. With progress made toward learning more ...
